Valeant Pharmaceuticals International (VRX)
- NYSE: VRX
- Mkt.Cap.:4.55B
Focused:
Healthcare > Biopharmaceuticals (^BPHRM)
Healthcare > Biopharmaceuticals (^BPHRM) Classification
| Sector | |
|---|---|
Healthcare |
|
Biopharmaceuticals |
|

- - Focused

- - Sector Pure-Play
Sector companies
Top 5 competitive companies in Biopharmaceuticals (^BPHRM) :
| Ticker | Name | Mkt.Cap. |
|---|---|---|
| PFE | Pfizer Inc. | 132.77B |
| NVS | Novartis AG (ADR) | 121.47B |
| RHHBY | Roche Holding Ltd. (ADR) | 120.28B |
| MRK | Merck & Co., Inc. | 110.98B |
| GSK | GlaxoSmithKline plc (ADR) | 102.01B |
Relationships
Sample 8 relationships grouped by relationhip type.
| Ticker | Name | |
|---|---|---|
| Competitors | ||
![]() | AGN | Allergan, Inc. |
![]() | BVF | Biovail Corporation (USA) |
| Customers | ||
![]() | CAH | Cardinal Health, Inc. |
![]() | MCK | McKesson Corporation |
| Suppliers | ||
![]() | MRK | Merck & Co., Inc. |
![]() | NVS | Novartis AG (ADR) |
| Partners | ||
![]() | AGN | Allergan, Inc. |
![]() | GSK | GlaxoSmithKline plc (ADR) |

- - Defined by the Company

- - Defined by Others
Products & Services
Sample products & services from Biopharmaceuticals (^BPHRM) :
- 8-MOP (Methoxsalen)
- Ancobon (Flucytosine)
- Aton Pharma, Inc. - Aton 001 (Injectable Vitamin K)
Relative Performance (1Y)
- Valeant Pharmaceuticals International (VRX)
- S&P 500 INDEX (SPX)
- Healthcare > Biopharmaceuticals (^BPHRM)
Subscribe to an RSS Feed Research Reports
- Competitors by Product for Valeant Pharmaceuticals International (VRX) Revere - Aug 21, 2010 - HTML - $75.00 - Add to Cart »
- Drug/Medical Device for Valeant Pharmaceuticals International (VRX) Revere - Aug 28, 2010 - PDF - $70.00 - Add to Cart »
- FDA Approval Decisions Report for August, 2010 Revere - Aug 01, 2010 - ZIP - $125.00 - Add to Cart »
- FDA Approval Decisions Report for July, 2010 Revere - Jul 01, 2010 - ZIP - $125.00 - Add to Cart »
- FDA Approval Decisions Report for June, 2010 Revere - Jun 01, 2010 - ZIP - $125.00 - Add to Cart »
Healthcare
Biopharmaceuticals